Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 07 - 06 tags : Fda save search
FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients
Published: 2021-07-06 (Crawled : 19:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -1.05%
H: 1.06%
C: -12.02%
treatment fda phase 2 opioid osteoarthritis trial fda clearance
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi SyndromeFDA agrees to review additional data to determine adequacy for submission of NDA
Published: 2021-07-06 (Crawled : 17:00) - biospace.com/
SLNO 4 | $37.15 -1.98% -2.02% 260K
|
Health Technology
|
| O: -0.91%
H: 0.92%
C: -2.75%
treatment fda submission
FDA and the CMC goalposts: CMC should accelerate, not curb, gene therapy progress
Published: 2021-07-06 (Crawled : 17:00) - avrobio.com
AVRO | $1.23 0.82% 0.81% 37K
|
Health Technology
|
| O: 1.01%
H: 1.44%
C: -5.87%
fda gene therapy therapy gene therapies
Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777
Published: 2021-07-06 (Crawled : 13:00) - globenewswire.com
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 1.17%
H: 0.35%
C: -4.1%
fda fda acceptance collaboration antibody
Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
OPT | $3.41 0.29% 0.29% 2.7K
|
Health Technology
|
| O: 11.8%
H: 1.28%
C: -4.87%
fda fda fast track fast track macular granted fast track designation grant designation
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.12%
H: 0.27%
C: -0.04%
fda fda approval approval keytruda cell carcinoma
ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
ANIP | News S | $64.6 -1.34% -1.36% 180K
|
Health Technology
|
| O: 1.1%
H: 1.65%
C: -6.04%
fda
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: -6.69%
H: 1.46%
C: -6.05%
treatment fda cancer breast cancer metastatic breast cancer
CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
CTSO | $0.8011 1.41% 1.39% 100K
|
Health Technology
|
| O: 2.07%
H: 12.34%
C: 10.67%
fda fda approval device iot cardio trial approval
Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
ISEE | $39.95 0.38% 0.38% 0
|
Health Technology
|
| O: 18.57%
H: 12.89%
C: 3.49%
fda phase 3 trial macular
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.